Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Acetaminophen  COVID-19 treatment studies for Acetaminophen  C19 studies: Acetaminophen  Acetaminophen   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Liver injury -41% Improvement Relative Risk Marín Dueñas et al. Acetaminophen for COVID-19 EARLY Is early treatment with acetaminophen beneficial for COVID-19? Retrospective 1,100 patients in Peru Higher progression with acetaminophen (p=0.045) Marín Dueñas et al., Annals of Hepatology, doi:10.1016/j.aohep.2021.100391 Favors acetaminophen Favors control
Alteration in liver function tests among patients hospitalized for COVID-19: a multicentric study in Peru
Marín Dueñas et al., Annals of Hepatology, doi:10.1016/j.aohep.2021.100391
Marín Dueñas et al., Alteration in liver function tests among patients hospitalized for COVID-19: a multicentric study in Peru, Annals of Hepatology, doi:10.1016/j.aohep.2021.100391
Sep 2021   Source   PDF  
  All Studies   Meta
Retrospective 1,100 COVID-19 patients in Peru, showing higher risk of liver injury with paracetamol use. Paracetamol is also known as acetaminophen.
risk of liver injury, 41.0% higher, OR 1.41, p = 0.045, liver injury, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Marín Dueñas et al., 30 Sep 2021, retrospective, Peru, peer-reviewed, median age 31.5, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAcetaminophenAll
Abstract: Abstracts P-25 SLOWER FIBROSIS PROGRESSION IN HEPATITIS C HEMOPHILIAC PATIENTS? Dauana O. Bastos, Christini Emori, Sandra V. Antunes, Flavia Appel, Maria Lucia Ferraz ~o Paulo, Sa ~o Paulo, Brazil Universidade Federal de Sa Introduction: The improvement in the treatment of hemophilia from the 900 s, as well as the advent of interferon-free therapy against HCV enabled a better evolution of these special group of patients. However, the impact of hemophilia on the progression of liver fibrosis is still not completely understood. Objectives: To evaluate the progression of liver fibrosis in hemophiliac patients with HCV using non-invasive methods after ten years of follow-up. Casuistic and Method: Retrospective cohort study of hemophiliac patients with HCV evaluated in 2007 and reassessed 10 years later (2017/2018). Hepatic fibrosis was indirectly evaluated by APRI and transient hepatic elastography by Fibroscan Ò - EHT). Results: Sixty-six hemophiliac patients were evaluated in 2007 (all men, median age 31.5 years, 87.9% hemophilia A). Forty-two patients could be reevaluated in 2017/2018. Thirty-three patients were treated with 90.9% SVR; thus, after 10 years, 30 patients were non-viremic and 12 were viremic (3 without SVR and 9 untreated). APRI values were low in both periods but showed a significant reduction in treated patients (0.36 vs 0.20, p <0.001), remaining stable in non-treated (0,61 vs 0,51, p=NS). Fibrosis by EHT was assessed only in 2017/2018 and also showed results compatible with low stages of fibrosis in treated and even in non-treated patients (4.75 and 5.25 kPa, respectively). Conclusions: After ten years of follow-up the results suggest a slower progression and a more benign evolution of hepatic fibrosis among hemophiliacs. Antiviral therapy against HCV showed an elevated response rate, similar to the general population. P-26 PORTAL VENOUS THROMBOSIS IN TRANSPLANTED CIRRHOTIC PATIENTS AT THE “HOSPITAL CLINICO UNIVERSIDAD DE CHILE” V.N. Henríquez Auba1, F. Ramirez1, M. Fabres2, P. Abarca2, B. Astrosa2, D. Vera1, J.C. Diaz3, J. Castillo3, 3, M. Cattaneo1, J. Poniachik1,3, H. Lembach3, A. Saure A. Urzua1,3 n de Gastroenterología, Universidad de Chile, Seccio Santiago, Chile 2 Universidad de Chile, Santiago, Chile 3 Universidad de Chile, Unidad de Trasplantes, Santiago, Chile 1 Background: Portal vein thrombosis (PVT) is a frequent complication in cirrhotic patients on the waiting list for liver transplantation (LT); this is associated with increased post-LT mortality. Objective: Characterize the presence of PVT in patients with LT. Methods: Retrospective observational study between January 1, 2014 and February 28, 2018. Clinical records, laboratory and images were reviewed. Results: 82 patients were included; Age 58 (21-71) years; Etiology: non-alcoholic fatty liver 40.2%, alcoholic liver disease 20.7%, autoimmunity 13.4%, and hepatitis C 8.5%; Child-Pugh: 7.3% A, 30.4% B and 62.2% C; MELD-Na 22 (8-40). PVT was diagnosed before or during LT in 26.8%: Child A 16.6%, B 16.0%, and C 33.3%; MELD-Na 25 (1240) in those with PVT vs 21 (8-40) in those without PVT (non significant, NS); 34% had hepatocarcinoma (32.1% with PVT vs. 24.4% Annals of Hepatology 24 (2021) 100366 without PVT; NS). Diagnosis of PVT was 77.2% pre LT and almost 1/4 during transplant surgery. The extension of the PVT was complete occlusion in 11.7%, partial in 70.5%; 11.7% had only intrahepatic branches compromised..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop